Concerns Over LaBrella: Veterinary Insights and Pet Owner Communication

Librela, a new drug to treat arthritis pain in dogs, was approved for use in Canada in 2021. In some cases, it was described to owners as a “miracle drug”, with no side effects other than potential soreness and swelling at the injection site. Some owners describe their dogs seeming happier and more comfortable. But others have reported adverse reactions, including lethargy, disorientation, vomiting, and even death. Zoetis, Librela’s parent company, says Librela is safe and was rigorously tested. 

Susan Krashinsky Robertson is a business reporter for the Globe. She spoke to eight people whose pets’ health declined after taking Librela. She’s on the show to talk about the promise of Librela, and what she heard from pet owners and veterinarians about the drug.

Questions? Comments? Ideas? Email us at  thedecibel@globeandmail.com